This year's Swiss Biotech Report[PDF] highlights the outstanding positioning of the entire value chain of the Swiss biotech industry within the international life sciences ecosystem. Success, innovation, research and financial growth can only be driven in cooperation with international stakeholders. SIX Swiss Exchange also plays a vital role in this respect, and is once again represented by an article in the report. The new report was presented at this year's Swiss Biotech Day
, the leading Swiss biotechnology conference.
Molecular Partners at the forefront of the upswing for Swiss biotech firms
Andrea von Bartenwerffer, Senior Relationship Manager Issuer Relations, and Seraina Benz, Relationship Manager Issuer Relations, moderated a roundtable dealing not only with the subject of IPOs as a funding option but also with the challenges posed by the various phases of the funding cycle for biotech companies.
With a special focus on the listing of Molecular Partners in November 2014, Andreas Emmenegger (CFO, Molecular Partners), Jean-Philippe Tripet (Chairman and Founder,Aravis) und Marc Klingelfuss (Managing Director, Bank Vontobel) discussed the challenges of capital-raising, current sentiment among investors and the future development of the biotech environment.
Europe's leading exchange for Life Sciences
SIX Swiss Exchange Exchange is Europe's leading exchange for Life Sciences companies and offers both Swiss and foreign companies an ideal environment for raising capital. To learn more about our advantages for equity issuers, you can watch our film, visit our website or read our publications.
